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 The phospholipid-binding annexin 
A2 (AnxA2) is known to play a role in the 
regulation of membrane and actin 
dynamics, in particular in the endocytic 
pathway. The protein is present on early 
endosomes, where it regulates membrane 
traffic, including the biogenesis of 
multivesicular transport intermediates 
destined for late endosomes. AnxA2 
membrane association depends on the 
protein N-terminus and membrane 
cholesterol, but does not involve the AnxA2 
ligand p11/S100A10. However, the precise 
mechanisms that control AnxA2 membrane 
association and function are not clear. In the 
present study, we have investigated the role 
of AnxA2 N-terminal phosphorylation in 
controlling association to endosomal 
membranes and functions. We found that 
endosomal AnxA2 was partially tyrosine-
phosphorylated, and that mutation of Tyr23 
to Ala (AnxA2Y23A), but not of Ser25 to 
Ala, impaired AnxA2 endosome association.  
We then found that the AnxA2Y23A mutant 
was unable to bind endosomes in vivo, while 
a phospho-mimicking AnxA2 mutant 
(Y23D) showed efficient endosome binding 
capacity. Similarly, we found that 
AnxA2Y23D interacted more efficiently 
with liposomes in vitro, when compared to 
AnxA2Y23A. To investigate the role of 
Tyr23 in vivo, AnxA2 was knocked down 
with siRNAs and then cells were re-
complemented with RNAi-resistant forms of 
the protein. Using this strategy, we could 
show that AnxA2Y23D, but not 
AnxA2Y23A, could restore early-to-late 
endosome transport after AnxA2 depletion. 
We conclude that phosphorylation of Tyr23 
is essential for proper endosomal association 
and function of AnxA2, perhaps because it 
stabilizes membrane-associated protein via 
a conformational change. 
 
Annexin family proteins, which can 
bind membranes via negatively charged 
phospholipids and Ca2+ ions (1), are considered 
as scaffolding proteins that can participate 
and/or regulate membrane dynamics and 
organization (2,3). Annexin A2 (AnxA2), a 
well-characterized member of this family, is 
composed of a non-folded and hyper-variable 
N-Terminal domain and of a very conserved 
C-terminal domain, which bears the common 
characteristics of annexins, including Ca2+ 
binding site and annexins repeats. The N-
terminus of AnxA2 binds p11/S100A10, the 
light-chain of anxA2, leading to formation of 
the (AnxA2)2-(p11)2 heterotetramer (4). 
AnxA2 N-terminus also bears two 
phosphorylation sites, on Tyr23 and Ser25, 
which are presumably targets of Src kinase and 
protein kinase C, respectively (5-7), but their 
precise(s) role(s) are still under debate. The 
phosphorylation of Ser25 may play a role in 
vesicles/granules aggregation (8,9). The 
phosphorylation of Tyr23 by Src kinase was 
proposed to act either as a targeting signal for 
the plasma membrane together with p11 
(10,11) or as a negative signal for (AnxA2)2-
(p11)2 heterotetramer formation or stabilization 
(12). The presence of AnxA2 at the plasma 
membrane may also facilitate tyrosine 
phosphorylation (13). Tyrosine 
phosphorylation has also been proposed to 
regulate actin AnxA2-related functions (14), 
notably in polarized epithelial cells (15). 
Finally, AnxA2 has been identified as a Lyn 
kinase target after oxidative stress and 
phosphorylation was proposed to induce 
AnxA2 relocalization to the endoplasmic 
reticulum (16). 
 
In fibroblastic cells or non-endothelial 
cells, AnxA2 is present at the plasma 
membrane, in the cytosol and also on early 
endosomes (2,17). Knockdown experiments by 
RNAi have shown that AnxA2 is involved in 
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early endosome membrane dynamics along the 
recycling (18) and degradation pathways 
(19,20). In particular, AnxA2 was shown to be 
required for the biogenesis of multivesicular 
transport intermediates destined for late 
endosomes (19,20). In contrast to other 
annexins, the endosomal association of AnxA2 
does not depend on Ca2+ (17,21), or p11 
binding and heterotetramer formation (20), but 
on membrane cholesterol (19,22,23). AnxA2 
shows a non-random distribution on early 
endosomal membranes, presumably 
corresponding to cholesterol-AnxA2 platforms 
or domains (22). In addition, AnxA2 
membrane association also requires the N-
terminus of the protein (19,21,23,24), which 
contains the Tyr23 and Ser25 phosphorylation 
sites. 
   
In the present article, we have 
analyzed the putative role of the 
phosphorylation of the AnxA2 N-terminal part 
in its association to early endosomes and in its 
endosomal functions. We show that purified 
endosomal anxA2 is tyrosine-phosphorylated 
and, by the use of phosphorylation mutants, we 
demonstrate that the phosphorylation of 
tyrosine 23 is required for a proper AnxA2 
targeting to early endosome. Moreover, using a 
siRNA phenotype rescuing, we demonstrate 
that the AnxA2 function in the endosomal 
transport is controlled by tyrosine 
phosphorylation. We conclude that AnxA2 
endosomal binding properties as well as the 
AnxA2 endosomal function are directly linked 
to tyrosine, but not serine, phosphorylation. 
 
EXPERIMENTAL PROCEDURES 
 
Cells, antibodies and reagents - Baby Hamster 
kidney cells (BHK21) and HeLa cells were 
grown as previously described (19,25). The 
monoclonal antibody against Rab5 was a gift 
from R. Jahn (Göttingen, Germany), 
monoclonal antibodies against AnxA2 (HH7 
and H28) and p11 (H21) were gifts from V. 
Gerke (Münster, Germany). Rabbit polyclonal 
antibodies against EEA1 (early endosomal 
antigen 1) and Lamp1 (lysosomal associated 
membrane protein 1) were from Alexis 
Biochemical and Affinity Bioreagents 
respectively. The monoclonal antibody against 
GFP was from Roche Diagnostics, against 
transferrin receptor from Zymed Laboratories, 
and against phosphotyrosine from 
Transduction Laboratories (PY20) and Upstate 
(4G10). The monoclonal antibody against actin 
and polyclonal antibody against anti-
phosphoserine were from Abcam. The rabbit 
polyclonal antibody against Rab7 was 
described (26,27). Peroxidase-conjugated 
secondary antibodies were from BioRad and 
Cy2, Cy3 and Cy5-conjugated fluorescent 
secondary antibodies were from Jackson 
Immunoresearch. The 10 kDa fluorescent fluid 
phase marker rhodamin-dextran was from 
Molecular Probes. F-actin was labeled with 
Allexa fluor 486nm coupled phalloidin from 
Invitrogen. All lipids and Latrunculin B were 
from Sigma.  
 
Plasmids, recombinant proteins and RNAi - 
cDNA plasmid coding for human 
AnxA2A65EGFP was a gift from V. Gerke 
(Münster, Germany). This plasmid is referred 
as AnxA2wtGFP in the paper. From this cDNA, 
we cloned several mutants of anxA2GFP by 
mutagenesis: anxA2dmtGFP 
(anxA2Y23AS25AGFP), in which Tyr23 and Ser25 
were replaced by alanine, anxA2Y23AGFP, 
anxA2Y23DGFP and anxA2S25AGFP. Similar 
recombinant AnxA2 constructions were 
obtained by cloning these cDNAs in pGEX-
5X-1 expressing vector (Clontech) and GST-
protein was produced in BL21 bacteria strain. 
The GST tag was removed by Factor Xa 
cleavage and benzamidine treatment 
(Amersham). The quality of recombinant 
protein was checked by SDS-PAGE and 
Coomassie staining. For mock-treated controls 
(ctrl) in RNAi experiments, we used VSV-G 
(Vesicular Stomatisis Virus, protein G) siRNA. 
AnxA2 downregulation was obtained by 
Dicer-generated siRNA duplexes (20). Briefly, 
an amplicon of the target sequence 
(nucleotides 1-320 from human AnxA2 cDNA, 
PCR oligos for T7-promoter based cloning: 
TAA TAC GAC TCA CTA TAA GGG AGA 
ATG TCT ACT GTT CAC G sense and TAA 
TAC GAC TCA CTA TAG GGA GAC TGA 
GCA GGT GTC TTC antisense) was 
transcribed in vitro to generate dsRNA; dicing 
reaction and d-siRNAs purification were done 
accordingly to the manufacturer’s instructions 
(Invitrogen). HeLa and BHK cells were 
transfected 6h after seeding with Fugene-6 
(Roche Diagnostics) for cDNA (total time of 
overexpression: 48h) and with lipofectamine 
2000 (Invitrogen), 24h after seeding, for RNAi 
experiments (total time for silencing: 72h). 
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In vivo endocytic transport assay - Cells were 
grown on coverslips and then incubated with 
3mg/mL rhodamin-dextran for 10min at 37°C 
in GMEM containing 10 mM Hepes. 
Alternatively, cells were re-incubated in 
marker-free medium for an additional 40min at 
37°C. Then, cells were fixed and processed for 
immunofluorescence, as below.  
 
Microscopy - Cells cultured on coverslips were 
fixed with 3% PFA and permeabilized with 
0.1% saponin in PBS with 10% serum buffer 
except when using special permeabilization 
buffer, before fixation, containing 0.1% Triton 
100X in 100mM KCl, 2mM MgCl2, 1mM 
CaCl2 and 1mM Hepes pH 6.9. Pictures were 
captured with a Zeiss Axiophot microscope, 
equipped with a 63x Plan-Neofluar objective, 
or with a Zeiss LSM 510 META confocal 
microscope equipped with a 63x Plan-
Apochromat objective and HeNe1, HeNe2 and 
Argon lasers. To quantify the colocalization 
between EEA1 and AnxA2GFP fusions proteins 
we counted the number of EEA1-positive 
structures that also contained AnxA2GFP per 
100µm2 in each focal plane. Similarly, the 
number of vesicles containing Lamp1 and 
rhodamin-dextran (after pulse-chase 
internalization as above) after mock-, AnxA2-
RNAi with or without AnxA2 cDNAs was 
quantified by counting the number of vesicles 
containing both markers per 100 µm2 in each 
focal plane. 
 
Subcellular fractionation - Early and late 
endosomes were purified as previously 
described (28). The analysis of total 
membranes and cytosol was carried out by 
high-speed centrifugation of post-nuclear 
supernatants (70.000 rpm for 30min). 
Membranes and cytosol were recovered from 
the high-speed pellet (HSP) and high-speed 
supernatant (HSS), respectively. 
 
Biochemical analysis - Total cell lysates were 
prepared using TNE buffer (20 mM tris pH 
7.4, 150 mM NaCl, 1 mM EDTA), and 
proteases inhibitors (10µM aprotinin, 10µM 
leupeptin and 1µM pepstatin) and 1% NP40. 
For immunoprecipitation assays, this lysis 
buffer was supplemented with 10% glycerol. 
Briefly, cell extracts or purified endosomes 
from transfected BHK or HeLa cells were 
diluted with TNE buffer to a final NP40 
concentration of 1%, complemented with 4µg 
anti-GFP antibody and proteinA-Sepharose 
beads (Amersham), and incubated for 2h at 
4°C. Beads were then washed with TNE buffer 
with 10% glycerol and resuspended in 
Laemmli buffer (29). Lysates and 
immunoprecipitates were analyzed by SDS-
PAGE, using 12% acrylamide gels, and 
western blotting. For p11 western blotting 
analysis, PVDF (Millipore) membranes were 
used. Western blotting was carried out using 
the SuperSignal® West Pico chemiluminescent 
substrate (Pierce Chemical Co); exposure 
times were always within the linear range of 
detection. Chemiluminescent signal was 
quantified with ImageJ software (NIH). 
 
Annexin A2 binding to liposomes - Five µg of 
purified recombinant protein (anxA2wt, 
anxA2Y23A, anxA2Y23D) were incubated 
with liposomes containing phosphatidic acid 
(PA):phosphatidylethanolamine 
(PE):cholesterol, (2:2:1) in 50mM Hepes, 
1mM EGTA (pH 7.4), 100mM KCl buffer, 
5µM DTT, 0.5mM MgCl2, 12.5mM Tris-HCl, 
4mg/ml cytosol prepared from BHK cells, 
phosphatase inhibitors (0.1mM NaF and 
10mM orthovanadate) and an ATP-
regenerating system for 30min at 4°C (30,31). 
In some experiments, the mixture was further 
incubated for 3h at 37°C, as indicated. The 
binding reaction was stopped by snap freezing 
in liquid nitrogen. Liposome-bound and free 
recombinant protein was separated by 
ultracentrifugation at 35.000 rpm for 60min at 
4°C, and analyzed by SDS gels and western 
blotting with the monoclonal H28 antibody 
was used against recombinant AnxA2. In 
immunoprecipitation experiments, liposomes 
after floatation were mixed with TNE buffer, 
brought to a final NP40 concentration of 1%, 
complemented with 2µg anti-AnxA2 antibody 
H28 and proteinA-Sepharose beads 
(Amersham), and incubated for 2h at 4°C. 
Beads were then washed with TNE buffer with 
10% glycerol and resuspended in Laemmli 
buffer (29). 
 
 
RESULTS AND DISCUSSION 
 
 Endosomal AnxA2 is phosphorylated 
on Tyr23. To investigate the possible role of 
AnxA2 phosphorylation in endosome 
association, cells were transfected with AnxA2 
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tagged with GFP (anxA2wtGFP), which shows 
the same distribution as the endogenous 
protein (20). After immunoprecipitation from 
total HeLa cell lysates with anti-GFP 
antibodies, phosphorylated AnxA2 could be 
revealed by western blotting with anti-
phosphotyrosine, but not anti-phosphoserine, 
antibodies (Fig 1A). As a control, we mutated 
the two known N-terminal phosphorylation 
sites Tyr23 and Ser25 to Ala (double mutant 
Y23AS25A, anxA2dmtGFP). Although 
expressed to the same levels as the WT 
protein, the mutant showed no detectable 
levels of phosphorylation after 
immunoprecipitation (Fig 1A). It thus appears 
that unstimulated cells contain AnxA2 
phosphorylated on Tyr23, but perhaps not on 
Ser25, under steady state conditions. 
 
Using a well-established fractionation 
protocol (28), early endosome fractions were 
prepared from BHK cells transfected with 
anxA2wtGFP. The recovery of early endosomes 
containing the early endosome markers Rab5 
and its effector EEA1, but not the late 
endosome marker Rab7, was not affected by 
anxA2wtGFP expression (Fig 1B). Western 
blotting with anti-phosphotyrosine and anti-
phospho-serine antibodies revealed that a 
fraction of endosomal anxA2wtGFP was 
phosphorylated on Tyr (figure 1C, right panel) 
but apparently not on serine (not shown).  
 
 Efficient endosome targeting depends 
on AnxA2 phosphorylation. Next, we 
investigated whether phosphorylation plays a 
role in the regulation of endosomal membrane 
binding, and analyzed the subcellular 
distribution of WT and mutant protein by 
confocal microscopy. The WT protein was 
present in the cytosol and colocalized with 
EEA1 on early endosomes (Fig 2A, 
arrowheads), as expected (19 ,20,28). By 
contrast, the mutant protein was predominantly 
cytosolic and showed little colocalization with 
EEA1 (Fig 2A arrowheads — the yellow color 
in the merge reflects the overlap between 
cytosolic anxA2dmtGFP and EEA1 punctae), as 
illustrated by the quantification of WT and 
mutant AnxA2 co-localization with EEA1 
(figure 2B). 
 
After homogenization and high speed 
centrifugation, anxA2wtGFP was enriched 
approximately 2 fold in membranes when 
compared to the cytosol fraction, like 
endogenous anxA2 (Fig 2C, quantification in 
the inset), as expected (23). By contrast, 
anxA2dmtGFP showed the opposite distribution, 
being enriched approximately 2 fold in cytosol 
(Fig 2C, quantification in the inset), in good 
agreement with our microscopy analysis 
(figure 2A). Finally, after endosome 
preparation by subcellular fractionation, both 
anxA2wtGFP and anxA2dmtGFP copurified with 
endogenous AnxA2 and the transferrin 
receptor and to a lesser extent with Rab7 — 
anxA2wtGFP was somewhat more abundant in 
late endosomes after overexpression (Fig 2D). 
Strikingly, however, early endosomes 
contained roughly half as much anxA2dmtGFP 
when compared to anxA2wtGFP (Fig 2D, 
quantification in inset), although the two 
proteins were expressed to similar levels (Fig 
2D). Altogether these observations show that 
membrane association of AnxA2 is impaired 
after mutagenesis of its phosphorylation sites. 
  
 Annexin A2 tyrosine phosphorylation 
is required for endosomal association. To 
identify which phosphorylation site, Tyr23 or 
Ser25, was necessary for endosome membrane 
association, we constructed two AnxA2 single-
point mutants, anxA2Y23AGFP and 
anxA2S25AGFP, in which Tyr23 or Ser25 had 
been mutated. Equal amounts of anxA2wtGFP, 
anxA2Y23AGFP and anxA2S25AGFP could be 
detected in total cell lysates (Fig 3A). Yet, 
after high speed centrifugation, anxA2S25AGFP 
shown the same distribution as the WT protein 
being more abundant than anxA2Y23AGFP (Fig 
3B). Similarly, after subcellular fractionation, 
anxA2S25AGFP and the WT protein were 
equally abundant on endosomes (Fig 3A). By 
contrast, anxA2Y23AGFP was significantly 
reduced (Fig 3A) and showed the same 
distribution as the double phosphorylation 
mutant (Fig 2D). 
  
To further investigate the role of Tyr23 
phosphorylation, we generated a phospho-
mimicking mutant by replacing the tyrosine 
residue with an aspartic acid (anxA2Y23DGFP). 
When analyzed by light microscopy, the two 
tyrosine mutants of anxA2 (AnxA2Y23AGFP 
and anxA2Y23DGFP) showed very different 
behavior. anxA2Y23AGFP was predominantly 
cytosolic (Fig 4A, quantification in Fig 4B), 
like the double mutant (Fig 2A). By contrast, 
anxA2Y23DGFP showed essentially the same 
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distribution as the WT protein. This mutant 
colocalized extensively with EEA1 on early 
endosomes, perhaps even more so that the WT 
protein (Fig 4A, quantification in Fig 4B). 
Similarly, anxA2Y23DGFP, but not 
anxA2Y23AGFP, showed the same distribution 
as the WT protein after fractionation (Fig 4C). 
Altogether, these observations demonstrate 
that endosome membrane association depends 
on Tyr23 phosphorylation of AnxA2. 
 
 Annexin A2 binding to liposomes. 
AnxA2 exhibits the intrinsic capacity to bind 
negatively charge phospholipids via its C-
terminal core domain, presumably in a 
calcium-dependent manner (2), and association 
to the endosomes depends on membrane 
cholesterol (19). Consistently, the purified 
recombinant form of AnxA2wt (Fig 5A) was 
able to bind efficiently liposomes containing 
phosphatidic acid (PA), phophatidyl-
ethanolamine (PE) and cholesterol after 
incubation for 30min at 4°C (19) (not shown). 
AnxA2wt also bound liposomes in the 
presence of cytosol, ATP and phosphatase 
inhibitors (Fig 5B) with the same efficiency as 
without cytosol (not shown). In these 
experiments, we used the H28 monoclonal 
antibody that recognizes the AnxA2 fusion 
proteins but not endogenous AnxA2 
(20,32,33). Similarly, AnxA2Y23A and 
AnxA2Y23D (Fig 5A), which both contain an 
intact C-terminus, showed the same liposome 
binding capacity as the WT protein in the 
presence (Fig 5B, quantification in Fig 5C) or 
absence (not shown) of cytosol, ATP and 
phosphatase inhibitors at 4°C. 
 
AnxA2wt was then incubated with 
liposomes in the presence of cytosol, ATP and 
and phosphatase inhibitors for 3h at 37°C. 
Liposomes were retrieved by floatation and 
AnxA2 was immuno-precipitated from the 
liposome fraction with the H28 anti-AnxA2 
antibody, which only recognizes the 
recombinant protein.  Immunoblotting of the 
precipitate with antibodies against phospho-
tyrosine showed that recombinant AnxA2wt 
bound to liposomes had been efficiently 
phosphorylated during the in vitro incubation 
(Fig 5D). Under these conditions, AnxA2wt 
was indeed detected on the liposomes (Fig 5B, 
lower panel) and binding occurred with an 
efficiency similar to that observed at 4°C (Fig 
5C). It is not easy to compare directly the 
absolute amounts of AnxA2wt bound at 4°C 
and 37°C, since the protein interacts with lipids 
and since bilayer fluidity is different at these 
temperatures. However, these experiments 
unambiguously show that AnxA2 is 
phosphorylated when bound to liposomes. 
  
 Strikingly, liposome association of 
AnxA2Y23A and AnxA2Y23D were 
significantly decreased and increased, 
respectively (Fig 5B, quantification in Fig 5C) 
after 3h at 37°C. This may reflect differences 
in the capacity of each mutant to interact with 
putative cytosolic partners. However, both 
mutants interacted with the AnxA2 light chain 
p11 with the same efficiency as the WT protein 
(Fig S1), indicating that p11 is unlikely to 
regulate membrane association, in accordance 
with our previous findings (20). We also found 
that actin, another well-established AnxA2 
partner, interacted preferentially with 
AnxA2Y23D when compared to AnxA2Y23A 
or to the wt protein (Fig S2), suggesting that 
Tyr23 phosphorylation regulates interactions 
with actin. Conversely, however, AnxA2 
membrane association is unlikely to be 
controlled by interactions with actin, since 
actin depolymerization with latrunculin B did 
not affect AnxA2 binding to endosomes (Fig 
S2). Thus, the simplest interpretation of our 
observations is that, the Y23D mutation, and 
presumably Tyr23 phosphorylation, increases 
membrane association at 37°C, when 
membrane fluidity is high, by causing a 
conformational change that stabilizes the 
protein onto the membrane. Consistently, we 
observed that liposome binding of AnxA2Y23D 
compared to AnxA2Y23A is increased, when 
the incubation was at 37°C without cytosol 
(Fig 5E). 
 
 Annexin A2 endosomal function 
requires tyrosine phosphorylation. We 
previously showed that AnxA2 depletion by 
RNA interference inhibits membrane transport 
beyond early endosomes along the pathway 
leading to lysosomes (19 ,20). To this end, we 
monitored early-to-late endosome transport 
using rhodamin-dextran internalized for 5min 
at 37°C and then chased for 40min in marker-
free medium. In control cells, the tracer 
reached Lamp1-positive late endocytic 
compartments, as expected, (Fig 6A; 
quantification in Fig 6C). After AnxA2 
knockdown with Dicer-generated siRNAs (Fig 
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6B), as in our previous studies (20), rhodamin-
dextran internalization was not affected (not 
shown), as expected (19,20). However, as in 
our previous studies  (19,20) little tracer 
reached Lamp1-positive late endosomes and 
intracellular levels were significantly 
decreased  (Fig 6A, quantification in Fig 6C) 
— most likely, the tracer had then been 
recycled to the medium, rather than transported 
to late endosomes and lysosomes. 
 
Next we investigated whether early-to-
late endosome transport could be restored by 
ectopic expression of the WT protein after 
AnxA2 depletion. After AnxA2 knockdown 
with siRNAs, anxA2wtGFP, anxA2Y23AGFP or 
anxA2Y23DGFP could be efficiently re-
expressed and expression levels were similar 
(Fig 6B). RNAi resistance was presumably due 
to the use of a modified human AnxA2 cDNA 
(nucleotide 197, (20,32,33)) that also contains 
a silent mutation in nucleotide 345 — the 
target sequence of our siRNA covers ≈350 first 
base pairs of human AnxA2 mRNA. 
Moreover, the two phosphorylation mutants 
bear mutations in nucleotide 70 (corresponding 
to Tyr23). Re-expression of the WT protein 
restored early-to-late endosome transport, 
unambiguously demonstrating that the 
inhibition of endocytic transport observed after 
AnxA2 depletion was not due to some off-
target effect (Fig 6A, quantification in Fig 6C). 
Strikingly, early-to-late endosome transport 
could be rescued by re-expression of the 
phospho-mimicking mutant anxA2Y23DGFP, 
but not of anxA2Y23AGFP (Fig 6A, 
quantification in Fig 6C). This observations 
show that Tyr23 is essential for AnxA2 
functions in endocytic membrane traffic, 
presumably because its phosphorylation 
regulates association to endosome membranes. 
 
CONCLUSION 
 
Endosomal AnxA2 is known to 
regulate endocytic membrane traffic, and in 
particular membrane transport from early to 
late endosomes (18-20,22), The protein shows 
a non-random distribution on endosomes, and 
is associated to membranes via an 
unconventional lipid-dependent mechanism 
(19,23), which requires the intact AnxA2 N-
terminus (2).  The hypervariable N-terminal 
domain of AnxA2 contains the Tyr23 and 
Ser25 phosphorylation sites as well as the 
binding site for p11/S100A10, the AnxA2 
ligand (2). While we previously found that 
p11/S100A10 is not involved in AnxA2 
endosomal functions (20), we now show that 
Tyr23 phosphorylation controls AnxA2 
binding to endosomal membranes, and thus its 
functions in transport — highlighting the role 
of the N-terminus, as recently suggested by in 
vitro approach with artificial membranes (34). 
 
Our experiments indicate that Tyr23 
phosphorylation regulates positively the 
binding of monomeric AnxA2 to endosomes. 
However, non-phosphorylated AnxA2 is also 
expected to be present on endosomes. In fact, 
our data argue that non-phosphorylable AnxA2 
can bind endosomes, but may be less 
efficiently retained onto the membrane. 
Phosphorylation may thus help stabilize 
AnxA2 onto the membrane, rather than acting 
as an “on-off” switch. It is tempting to propose 
that monomeric AnxA2 binds endosomes 
independently of Tyr23 phosphorylation, via 
phospholipids and cholesterol (2,19,22): 
phosphorylation may then stabilize membrane-
associated protein, perhaps via a 
conformational change that may help dipping 
of the amphipatic N-terminal helix into the 
bilayer, and/or facilitate oligomerization of 
AnxA2.  
 
In conclusion we show here that both 
binding and transport-related functions of 
endosomal AnxA2 are positively regulated by 
tyrosine phosphorylation in the N-Terminal 
part of the protein, highlighting the fact that 
AnxA2 functions are differentially regulated 
by specific signaling mechanisms on the 
different subcellular sites. 
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FIGURES LEGENDS 
 
Fig. 1. endosomal AnxA2 is phosphorylated on tyrosine 23. (A), HeLa cells were transfected with 
anxA2wtGFP or with anxA2dmtGFP, in which both Tyr23 and Ser25 were mutated to Ala. Cells were 
homogenized and the GFP fusion proteins were immunoprecipitated from the lysates with anti-GFP 
antibodies (IP Ab+: immunoprecipitate; IP Ab- : control without the specific antibody; load: input 
fraction before immunoprecipitation). Immunoprepipitates and one tenth of the load volumes were 
analyzed by SDS-PAGE and western blotting with the indicated antibodies: anti-GFP antibody (upper 
panels), anti-phosphoserine (middle panels) and anti-phosphotyrosine (lower panels). IgG HC, heavy 
chain of anti-GFP antibody used for immunoprecipitation. (B), BHK cells were (anxA2wtGFP) or not 
(NT) transfected with anxA2wtGFP. Early endosomes were prepared using a well-established 
fractionation protocol (28), and analyzed by SDS-PAGE and western blotting. The fractions contain 
the early endosomal markers EEA1 and Rab5, but not the late endosomal marker Rab7. (C), 
anxA2wtGFP was immunoprecipitated with anti-GFP antibodies from early endosomal fractions 
prepared as in (B). Ab+: immunoprecipitate; Ab-: control without the specific antibody; EE load: input 
fraction before immunoprecipitation (early endosomes). Immunoprepipitates and half of the load 
volumes analyzed by SDS-PAGE and western blotting with the indicated antibodies. IgG HC, heavy 
chain of anti-GFP antibody used for immunoprecipitation. 
 
Fig. 2. AnxA2 phosphorylation mutants and early endosomes localization. (A), HeLa cells were 
transfected with anxA2wtGFP (left panel) and anxA2dmtGFP (right panels), labeled with antibodies 
against EEA1 and analyzed by double channel fluorescence microscopy. Arrows point at examples of 
GFP-fusion protein colocalization with EEA1. Bar 10 µm. (B), the number of GFP-labeled structures 
that also contained EEA1 was counted and is expressed as a percentage of anxA2wtGFP. n=5. (C), BHK 
cells were transfected with anxA2wtGFP or anxA2dmtGFP, and homogenized. The lysate was 
fractionated by high speed centrifugation, and pellets (membranes, memb) and supernatants (cytosol) 
were analyzed by SDS-PAGE (equal protein amounts loaded in each lane) and blotted using anti-GFP 
antibody (upper panels) and anti-AnxA2 HH7 antibody (lower panel). The blots were scanned and the 
inset shows the fold enrichment in membranes over the cytosol. n=5. (D) BHK cells were transfected 
with anxA2wtGFP or anxA2dmtGFP. Early (EE) and late (LE) endosomes were prepared using the same 
fractionation protocol as in Fig 1B-C and analyzed by SDS-PAGE and western blotting using the 
indicated antibodies (equal protein amounts loaded in each lane). The early endosome blots were 
scanned and the amounts of anxA2dmtGFP present in early endosomes are expressed as a percentage of 
the anxA2wtGFP control. n=8. 
 
Fig. 3. Association of tyrosine 23 and serine 25 mutants to membranes. (A), BHK cells were 
transfected with anxA2wtGFP, anxA2Y23AGFP or anxA2S25AGFP. Cell lysates (upper panels) and early 
endosomes (EE, lower panels) were prepared and analyzed by SDS gels (equal protein amounts loaded 
in each lane) and blotted with anti-GFP and anti-rab5 antibodies. (B), Cells were transfected as in (A) 
and membranes (memb) and cytosol prepared as in Fig 2C were analyzed by SDS-PAGE (equal 
protein amounts loaded in each lane) and blotted using anti-GFP antibody and anti-Rab5 antibody.  
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Fig. 4. Distribution of AnxA2 single tyrosine mutant. (A), HeLa cells were transfected with 
anxA2wtGFP, anxA2Y23AGFP or anxA2Y23DGFP and analyzed by immunofluorescence using antibodies 
against EEA1. Bar 10 µm, arrowheads point at examples of GFP colocalization with EEA1. (B) As in 
Fig 2B, the number of GFP-labeled structures that also contained EEA1 was counted and is expressed 
as a percentage of anxA2wtGFP. n=3. (C), Early endosomes  were prepared from BHK cells transfected 
with anxA2wtGFP, anxA2Y23AGFP or anxA2Y23DGFP, analyzed by SDS-PAGE (equal protein amounts 
loaded in each lane) and blotted with anti-GFP antibody (upper panel) and antibodies against annexin 
A2, and rab5 (lower panels). 
 
Fig. 5. Binding to liposomes. (A) AnxA2wt, anxA2Y23A or anxA2Y23D were expressed in bacteria, 
purified and analyzed in SDS gels. The gels were stained with Coomassie blue. (B) PA/PE/cholesterol 
liposomes were prepared and incubated in vitro with 5µg purified recombinant anxA2wt, anxA2Y23A 
or anxA2Y23D, for 30min at 4°C in the presence of cytosol, ATP-regenerating system and phosphatase 
inhibitors (upper panel) or further incubated for 3h at 37°C (lower panel) in the same mixture, as 
indicated. Liposomes were then recovered by floatation in sucrose gradients and separated from the 
load containing free protein. Liposome-bound (bound) and free AnxA2 were analyzed by SDS-PAGE 
and western blotting using H28 monoclonal antibody that recognizes the recombinant proteins. (C), 
the blots in (B) were scanned and the amounts of recombinant protein associated to liposomes are 
expressed as a percentage of the AnxA2wt. n=3. (D) PA/PE/cholesterol liposomes were prepared and 
incubated in vitro with 5µg purified recombinant anxA2wt for 30min at 4°C in the presence of cytosol, 
ATP-regenerating system and phosphatase inhibitors and then for 3h at 37°C, as in B. Liposomes were 
then recovered by floatation in sucrose gradients and recombinant anxA2 was immunoprecipitated 
from the liposome fraction with H28 anti-annexin A2 antibody. The immunoprecipitate and the initial 
reaction mixture (react mix) were analyzed by SDS-PAGE and western blotting using the H28 
monoclonal antibody (right panel) and anti-phosphorylated tyrosine antibody (P-tyr, left panel). The 
position of AnxA2 is indicated with an arrow. The heavy chain of IgG used in immunoprecipitation is 
also indicated (IgG HC). (E) PA/PE/cholesterol liposomes were incubated in vitro with 5µg purified 
recombinant AnxA2Y23A or AnxA2Y23D for 3h at 37°C as in (B), but without cytosol, ATP 
regenerating system or phosphatase inhibitors. The panel shows a representative experiment analyzed 
as in (B). 
 
Fig. 6. Re-expression of AnxA2 mutants after knockdown. (A-B), AnxA2 was (siRNA) or not 
(control, ctrl) knocked down in HeLa cells with diced siRNAs (20). Then, cells were or not transfected 
with anxA2wtGFP, anxA2Y23AGFP or anxA2Y23DGFP cDNAs, as indicated. Cells were either 
homogenized and analyzed  by SDS-page and western blotting with the indicated antibodies (B) or 
incubated with rhodamine-dextran (red channel) for 10min at 37°C followed by a 40min chase without 
the marker (A). Then, cells were fixed and labeled with antibodies against lamp1 (blue channel). Bar: 
10µm. (C). The number of endosomes containing dextran and Lamp1 was counted and is expressed ad 
a percentage of the total number in the untreated control. n=4. 
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